Table 2.
Assessment of the type of treatment and selected parameters.
| Characteristic | Number of Cases (n) | First-Line Treatment Used (%) | Independence Assessment p Value |
Correlation Assessment φc or rφ * |
|
|---|---|---|---|---|---|
| Three-Drug Treatment | Two-Drug Treatment | ||||
| Sex | |||||
| Male | 100 | 80 (80.0%) | 20 (20.0%) | 0.999 | - |
| Female | 97 | 77 (79.4%) | 20 (20.6%) | ||
| ISS | φc | ||||
| ISS I | 25 | 21 (84.0%) | 4 (16.0%) | 0.602 | 0.081 |
| ISS II | 66 | 55 (83.3%) | 11 (16.7%) | ||
| ISS III | 96 | 74 (77.0%) | 22 (23.0%) | ||
| Presence of bone changes | |||||
| Yes | 154 | 125 (81.2%) | 29 (18.8%) | 0.644 | - |
| No | 36 | 28 (77.8%) | 8 (22.2%) | ||
| Calcium level above 2.75 mmol/L | |||||
| Yes | 28 | 25 (89.3%) | 3 (10.7%) | 0.305 | - |
| No | 168 | 132 (78.6%) | 36 (21.4%) | ||
| Creatinine above 1.9 mg/dL | |||||
| Yes | 44 | 28 (63.6%) | 16 (36.4%) | 0.005 | - |
| No | 153 | 129 (84.3%) | 24 (15.7%) | ||
| ECOG | φc | ||||
| ECOG 0 | 16 | 14 (87.5%) | 2 (12.5%) | 0.866 | |
| ECOG 1 | 84 | 68 (81.0%) | 16 (19.0%) | ||
| ECOG 2 | 71 | 54 (76.1%) | 17 (23.9%) | 0.090 | |
| ECOG 3 | 18 | 14 (77.8%) | 4 (22.2%) | ||
| ECOG 4 | 8 | 7 (87.5%) | 1 (12.5%) | ||
| Physical fitness, according to Katz | φc | ||||
| Fully independent | 158 | 130 (82.3%) | 28 (17.7%) | 0.162 | 0.139 |
| Moderate impairment | 23 | 15 (65.2%) | 8 (34.8%) | ||
| Completely dependent | 11 | 9 (81.8%) | 2 (18.2%) | ||
| Frailty score (IMWG) | rφ | ||||
| Intermediately fit | 43 | 34 (85.0%) | 9 (15.0%) | 1.000 | −0.010 |
| Frailty | 154 | 123 (79.8%) | 31 (20.8%) | ||
Abbreviations: ECOG—Eastern Cooperative Oncology Group; ISS—International Staging System. * Cramer’s V correlation (φc); Phi correlation (rφ); IMWG—International Myeloma Working Group.